Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results

Soleno Therapeutics (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial results for the fourth quarter and year ended December 31, 2017.

As quoted in the press release:

“The past 12 months have been transformative for our company,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno.  “In March of 2017, we completed the merger with Essentialis and refocused our business on the development of novel therapeutics for the treatment of rare diseases.  In the short period of time since then, we have advanced our lead product candidate, Diazoxide Choline Controlled-Release (“DCCR”) for the treatment of Prader-Willi Syndrome (“PWS”), towards a Phase III clinical trial, which we expect to initiate shortly.  As a result of meetings with the U.S. Food and Drug Administration (“FDA”) for DCCR in PWS, we now have alignment with the agency on key aspects of the planned Phase III clinical trial.”

Click here to read the full press release.